Drug Profile

Personalised prostate cancer therapy - BriaCell Therapeutics

Alternative Names: Bria-Pros; Bria-Pros+

Latest Information Update: 11 Aug 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator BriaCell Therapeutics Corp
Class Antineoplastics; Cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Cell replacements; Immunologic cytotoxicity

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Prostate cancer

Most Recent Events

05 Aug 2026 US FDA approves IND application for personalised prostate cancer therapy in Prostate cancer
21 Apr 2026 Pharmacodynamics data from a preclinical trial in Solid tumours released by BriaCell Therapeutics
06 Nov 2025 Pharmacodynamics data from a preclinical trial in Prostate cancer released by BriaCell Therapeutics

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com